The FDA discovered "important deficiencies" in data that support the beneficial effects of anemia treatment drugs Epogen and Aranesp made by Amgen and Procrit made by Johnson & Johnson. Studies that support quality-of-life improvement claims are limited and may not comply with current regulatory requirements, the FDA commented. More research is required to develop safer dosing recommendations, according to the FDA.

Related Summaries